Inhibikase Therapeutics Financial Overview
Inhibikase Therapeutics's market cap is currently $186.75M. The company's EPS TTM is $-0.13; its P/E ratio is -2.84; Inhibikase Therapeutics is scheduled to report earnings on November 14, 2025, and the estimated EPS forecast is $-0.12. See an overview of income statement, balance sheet, and cash flow financials.
